Cell delivery devices for cancer immunotherapy

Ping Wen; Wei Wu; Feifan Wang; Hanqi Zheng; Ziyan Liao; Jiaqi Shi; Chaojie Zhu; Peng Zhao; Hao Cheng; Hongjun Li; Zhen Gu

doi:10.1016/j.jconrel.2022.11.041

Cell delivery devices for cancer immunotherapy

J Control Release. 2023 Jan:353:875-888. doi: 10.1016/j.jconrel.2022.11.041. Epub 2022 Dec 19.

Authors

Ping Wen¹, Wei Wu², Feifan Wang¹, Hanqi Zheng¹, Ziyan Liao¹, Jiaqi Shi¹, Chaojie Zhu³, Peng Zhao², Hao Cheng⁴, Hongjun Li⁵, Zhen Gu⁶

Affiliations

¹ Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
² Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
³ Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Department of Hepatobiliary and Pancreatic Surgery the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
⁴ Department of Materials Science and Engineering, Drexel University, Philadelphia, PA 19104, USA. Electronic address: hcheng@drexel.edu.
⁵ Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Department of Hepatobiliary and Pancreatic Surgery the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China. Electronic address: hongjun@zju.edu.cn.
⁶ Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China; Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China; Jinhua Institute of Zhejiang University, Jinhua 321299, China; MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310027, China. Electronic address: guzhen@zju.edu.cn.

PMID: 36442617
DOI: 10.1016/j.jconrel.2022.11.041

Abstract

Adoptive cell therapy (ACT) that leverages allogeneic or autologous immune cells holds vast promise in targeted cancer therapy. Despite the tremendous success of ACT in treating hematopoietic malignancies, its efficacy is limited in eradicating solid tumors via intravenous infusion of immune cells. With the extending technology of cancer immunotherapy, novel delivery strategies have been explored to improve the therapeutic potency of adoptively transferred cells for solid tumor treatment by innovating the administration route, maintaining the cell viability, and normalizing the tumor microenvironment. In this review, a variety of devices for cell delivery are summarized. Perspectives and challenges of cell delivery devices for cancer immunotherapy are also discussed.

Keywords: CAR-T cells; Cancer therapy; Cell therapy; Drug delivery; Immunotherapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Hematologic Neoplasms*
Humans
Immunotherapy
Immunotherapy, Adoptive
Neoplasms* / therapy
T-Lymphocytes
Tumor Microenvironment